Mental health disorders are relatively common in the general population and were already an important issue for the healthcare sector before COVID-19. COVID-19, being a worldwide crucial event and evidently a great stressor has increased both the prevalence and incidence of these. Therefore, it is evident that COVID-19 and mental health disorders are closely related. Moreover, several coping strategies exist to endure said disorders such as depression and anxiety, which are used by the population to confront stressors, and healthcare workers are not the exception. This was an analytical cross-sectional study, conducted from August to November 2022, via an online survey. Prevalence and severity of depression, anxiety, and stress were assessed via the DASS-21 test, and coping strategies were assessed via the CSSHW test. The sample consisted of 256 healthcare workers and of those, 133 (52%) were males with a mean age of 40.4 ± 10.35, and 123 (48%) were females with a mean age of 37.28 ± 9.33. Depression was prevalent in 43%, anxiety in 48%, and stress in 29.7%. Comorbidities were a significant risk factor for both depression and anxiety with an OR of 10.9 and 4.18, respectively. The psychiatric background was a risk factor for depression with an OR of 2.17, anxiety with an OR of 2.43, and stress with an OR of 3.58. The age difference was an important factor in the development of depression and anxiety. The maladaptive coping mechanism was prevalent in 90 subjects and was a risk factor for depression (OR of 2.94), anxiety (OR of 4.46) and stress (OR of 3.68). The resolution coping mechanism was a protective factor for depression (OR of 0.35), anxiety (OR of 0.22), and stress (OR of 0.52). This study shows that mental health disorders are highly prevalent among healthcare workers in Mexico and that coping strategies are associated with their prevalence. It also implies that not only occupations, age, and comorbidities might affect mental health, but also the way patients confront reality and the behavior and decisions they take towards stressors.

Introduction: The burden of disease measures the total impact of diseases on a population, considering incidence, prevalence, disability, and premature mortality. This study analyzes the burden of ischemic heart disease (IHD) in Tabasco, Mexico, from 2013 to 2021. Ischemic heart disease has a significant incidence of 21,203,479 cases worldwide, and nationally (inside Mexico) a total of 221,747 cases, with more than 9,137,791 deaths due to this pathology globally. Objective: To analyze the burden of ischemic heart disease in Tabasco, Mexico, during the 2013–2021 period. Methods: An observational, descriptive, longitudinal, and retrospective study was conducted in Tabasco. The study population consisted of 2,402,598 people according to INEGI, with a sample of 927,000 adults (462,000 men and 465,000 women). Data were used from the General Directorate of Health Information, IHME, and the World Bank. Analyses were performed in Microsoft Excel, calculating measures of central tendency, dispersion, and Disability-Adjusted Life Years (DALYs). Results: The DALYs in the adult population of Tabasco were: 2013—23,932; 2014—28,132; 2015—30,197; 2016—30,683; 2017—31,839; 2018—38,599; 2019—40,046; 2020—42,307; and 2021—55,723, totaling 297,576 DALYs from 2013 to 2021. Discussion: Ischemic heart disease increased in incidence and mortality in both men and women during the years analyzed. The increase in DALYs indicates a greater impact of ischemic heart disease in Tabasco compared to countries like Costa Rica. Conclusion: The burden of ischemic heart disease from 2013 to 2021 represents a significant loss of quality and years of life in the population of Tabasco, Mexico.

Background: Persistent cognitive and neuropsychiatric symptoms have been increasingly reported as part of the post-COVID-19 condition. Neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) are circulating biomarkers of neuronal and astrocytic injury that increase during acute SARS-CoV-2 infection; however, their role in long-term neuropsychiatric sequelae remains unclear. Objective: To provide a narrative overview of cognitive and neuropsychiatric sequelae following SARS-CoV-2 infection and to explore the association of plasma NfL and GFAP concentrations with cognitive impairment and neuropsychiatric symptoms in individuals recovered from COVID-19. Methods: A narrative review of the literature was conducted, followed by an exploratory cross-sectional study including 41 adults recovered from SARS-CoV-2 infection. Participants were classified according to acute disease severity into two groups. Cognitive function was assessed using MoCA, and neuropsychiatric symptoms were evaluated using DASS-21. Plasma NfL and GFAP concentrations were measured by ELISA. Group comparisons and Spearman correlation analyses were performed. Results: A total of 41 individuals were studied; they recovered from moderate or severe COVID-19 and exhibited a higher prevalence of cognitive impairment and neuropsychiatric symptoms compared with those who recovered from mild or asymptomatic infection. Plasma NfL and GFAP concentrations did not differ significantly between severity groups. NfL showed a weak association with the presence of post-COVID-19 condition. Conclusions: This study highlights the high burden of persistent cognitive and neuropsychiatric symptoms following moderate and severe SARS-CoV-2 infection. The absence of sustained elevations in circulating NfL and GFAP nearly two years after infection suggests that ongoing symptoms may involve mechanisms beyond overt neuronal or astrocytic injury.

Introduction: The burden of disease measures the total impact of diseases on a population, considering incidence, prevalence, disability, and premature mortality. This study analyzes the burden of ischemic heart disease (IHD) in Tabasco, Mexico, from 2013 to 2021. Ischemic heart disease has a significant incidence of 21,203,479.22 cases worldwide, and nationally (inside Mexico) with a total of 221,747.28 cases, with more than 9,137,791 deaths due to this pathology globally. Objective: To analyze the burden of ischemic heart disease in Tabasco, Mexico, during 2013-2021. Methods: An observational, descriptive, longitudinal, and retrospective study was conducted in Tabasco (2013-2021). The study population consisted of 2,402,598 people according to INEGI, with a sample of 927,000 adults (462,000 men and 465,000 women). Data were used from the General Directorate of Health Information, IHME, and the World Bank. Analyses were performed in Microsoft Excel, calculating measures of central tendency, dispersion, and Disability-Adjusted Life Years (DALYs). Results: The DALYs in the adult population of Tabasco were: 2013: 23,932; 2014: 28,132; 2015: 30,197; 2016: 30,683; 2017: 31,839; 2018: 38,599; 2019: 40,046; 2020: 42,307; and 2021: 55,723, totaling 297,576 DALYs from 2013 to 2021. Discussion: Ischemic heart disease increased in incidence and mortality in both men and women during the last years analyzed. The increase in DALYs indicates a greater impact of ischemic heart disease in Tabasco compared to countries like Costa Rica. Conclusion: The burden of disease due to ischemic heart disease from 2013 to 2021 represents a significant loss of quality and years of life in the in the population of Tabasco, Mexico.

Background: The burden of type 2 diabetes mellitus (T2DM) in Tabasco from 2013 to 2023 has led to a significant loss in quality of life and life years. This study aims to analyze the impact of T2DM on the population of Tabasco, Mexico, during this period. Methods: A descriptive, observational, longitudinal, and retrospective study was conducted in Tabasco, following Feinstein’s guidelines. The study included 2,402,598 individuals, covering the adult study population of Tabasco (n = 927,047) based on National Institute of Statistics and Geography (INEGI) data. Data were gathered from the General Directorate of Health Information and the Ministry of Health and analyzed using Microsoft Excel, applying central tendency and dispersion measures, and calculating Disability-Adjusted Life Years (DALYs) with validated formulas. Results: DALYs in Tabasco’s adult population from 2013 to 2023 were 23,049 in 2013, 24,576 in 2014, 25,193 in 2015, 34,361 in 2016, 29,771 in 2017, 29,309 in 2018, 29,959 in 2019, 28,087 in 2020, 26,451 in 2021, 23,502 in 2022, and 30,523 in 2023, totaling 304,781 DALYs for the period. Conclusions: T2DM has shown an increase in incidence and mortality, especially in recent years, leading to a significant rise in DALYs. This reflects a higher disease burden in Tabasco compared to other regions in Mexico and the Americas, resulting in a considerable loss of quality of life and life years.